Feanalytic’s novel diagnostic method for detecting and monitoring inflammatory bowel disease (IBD)
IBD is a severe incurable autoimmune disease. Its main subtypes are ulcerative colitis and Crohn’s disease. IBD is also a major risk factor for colorectal cancer. Today up to 8 million people have been diagnosed with IBD and its prevalence is expected to increase.
Feanalytic develops a new non-invasive diagnostic assay to detect and monitor IBD and its subtypes. The new diagnostic tool will improve IBD diagnosis and treatment planning.